Why GT Biopharma’s B7-H3 TriKE could reshape immunotherapy for solid tumors
GT Biopharma’s GTB-5550 gets FDA clearance for a Phase 1 solid tumor trial. Find out how this NK cell engager could reshape B7-H3 cancer immunotherapy.
GT Biopharma submits IND for GTB-5550 TriKE targeting B7-H3 expressing solid tumors with NK cell activation
Find out how GT Biopharma’s IND filing for its B7-H3-targeted TriKE GTB-5550 could advance NK cell immunotherapy for solid tumors.
Aktis Oncology raises $318m IPO: What this means for alpha radiotherapy biotech bets
Can Aktis Oncology’s IPO jumpstart alpha radiopharma? Find out what its $318M raise means for solid tumor treatment and VC-to-IPO biotech strategy.
T-MAXIMUM’s MT027 clears FDA hurdle for glioblastoma in major step for solid tumor CAR-T
T-MAXIMUM’s MT027 CAR-T therapy for glioblastoma enters Phase II after FDA clearance. Find out what this means for solid tumor cell therapy.